Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zipalertinib, Carboplatin, and Pemetrexed in Resectable EGFR-Mutated NSCLC
NCT07229339Phase 2Not yet recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jun 2027
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zipalertinib in non-small cell lung cancer (NSCLC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07229339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229339.